OS Therapies Incorporated (OSTX)

OS Therapies will go public soon, but the exact IPO date is still unknown.
IPO Price
Shares Offered
Deal Size
Chart not available yet
Data will show when the stock starts trading.
Market Cap 82.39M
Revenue (ttm) n/a
Net Income (ttm) -6.38M
Shares Out 20.60M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About OSTX

OS Therapies Incorporated is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma and other solid tumors. Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults. Our pipeline includes two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 3
Ticker Symbol OSTX
Full Company Profile

Financial Performance

Financial Statements


OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma

ROCKVILLE, Md.--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic can...

6 weeks ago - Business Wire

OS Therapies IPO Registration Document (S-1)

OS Therapies has filed to go public with an IPO on the NYSE American.

1 year ago - SEC